“A patient’s IDH1 status helps determine eligibility for clinical trials, which offers more treatment options, and may one day lead to potential targeted therapies for people fighting brain cancer,” said Matt Sause, CEO of Roche Diagnostics.
Time is critical for patients fighting brain cancer. Patients diagnosed with glioblastoma have an average survival rate of less than one year. Having an understanding of a glioma patient’s mutation status will enable clinicians to quickly determine the optimum treatment path for that patient and help predict therapeutic outcomes.
Immunohistochemistry is recommended by all major glioma practice guidelines for determining IDH1 R132H and ATRX mutation status. When compared to sequencing, identification of IDH1 R132H mutations via immunohistochemistry has been shown to be more accurate, rapid, accessible and cost effective. The IDH1 assay can also detect the IDH1 R132H mutation in acute myeloid leukaemia (AML).
Roche’s IDH1 and ATRX assays are optimised and fully-automated on the BenchMark series of instruments. The two tests are now available in the US. They will likely be available in other non-CE markets later this year and in countries that accept the CE mark in 2024.
For more information, visit www.roche.com.
Digital issue: Please click here for more information